Cardiology Today, October 2017
Wendy Bottinor, MD
During the past decade, an explosion of novel cancer therapies has led to a significant increase in cancer survivorship. However, CVD is a leading cause of morbidity and mortality in patients with cancer treated with therapies as well as cancer survivors, which number 15.5 million Americans today. Several factors contribute to this, including CV and cardiometabolic toxicities from cancer treatments themselves.
Most cardiologists are familiar with the CVD profiles associated with traditional therapeutic strategies such as anthracyclines and radiation therapy. However, several novel therapies have been developed, including targeted tyrosine kinase inhibitors (TKIs), multitargeted TKIs, hormonal deprivation therapy, immunomodulatory drugs, proteasome inhibitors and immune checkpoint inhibitors. These agents have their own unique CVD profiles. Cardiologists will benefit from knowledge of the specific cardiac effects of these agents.